Doseology Completes Extensive North American Diligence, Securing Strategic Manufacturing Agreement via U.S. Subsidiary Doseology USA Inc.

Executive Summary

• Doseology Sciences’ U.S. subsidiary, Doseology USA Inc., signed a confidential manufacturing agreement with an FDA‑registered, GMP‑certified North American production partner.
• The partnership provides end‑to‑end pouch formulation, blending, filling, packaging and logistics capabilities, enabling the company to move from R&D to commercial deployment of oral stimulant pouches in the U.S. market.
• Management highlights that the agreement establishes a scalable, low‑risk manufacturing backbone, supporting pilot runs through high‑volume production and signaling readiness for market entry and shareholder value creation.

Key Details

• Agreement Scope: Confidential terms; partner is an FDA‑registered, GMP‑certified, ISO 9001:2015‑approved facility offering turnkey manufacturing for nicotine, caffeine, and nootropic oral pouches.
• Operational Benefits:
• Full‑service capabilities – formulation, ingredient sourcing, blending, pouch filling, packaging, logistics.
• Scalable production volumes to support early pilot runs, regional launches, and full commercial scale.
• Built‑in QA, traceability, labeling aligned with FDA and ISO standards.
• Strategic Impact: Provides the “commercial infrastructure, manufacturing capacity, and regulatory foundation” needed for Doseology’s transition from development to market readiness.
• Leadership Statements:
• Tim Corkum (President & COO) called the agreement a “defining moment” that moves the company from R&D to commercial deployment.
• Patrick Sills (Strategic Commercialization Advisor) emphasized the partnership’s alignment with industry best practices demonstrated by market leaders such as Swedish Match (ZYN).
• Shareholder Implication: Management asserts the deal validates readiness to scale, reduces capital investment risk, and creates a disciplined pathway toward value creation for shareholders.

Notable Quotes

“This is much more than a manufacturing agreement, it’s a defining moment as it enables Doseology to move from R&D to commercial deployment.” – Tim Corkum, President & COO

“Having worked closely with global category leaders such as Swedish Match… this partnership validates the Company’s commitment to execution, quality, and shareholder value.” – Patrick Sills, Strategic Commercialization Advisor